Promising and Upcoming Treatments in Myositis

Lauren N. Smith, Julie J. Paik

Research output: Contribution to journalReview articlepeer-review


Purpose of Review: To highlight new and emerging treatment targets in myositis. Recent Findings: The landscape of novel therapeutics in myositis has vastly changed in the past 5 years. This is largely due to a greater understanding of the pathogenesis of myositis and validation of more robust outcome measures that standardize the ability to assess treatment response. Clinical trials in dermatomyositis are leading the way with ongoing multicenter, international phase 3 clinical trials. Proof-of-concept studies targeting the JAK/STAT pathway have also showed early promise in treating refractory dermatomyositis in adults and children. Summary: This review highlights that the future armamentarium of therapeutic drugs will likely be larger and more selective in treating different subgroups of myositis.

Original languageEnglish (US)
Article number65
JournalCurrent rheumatology reports
Issue number10
StatePublished - Oct 1 2020


  • Dermatomyositis
  • Immune-mediated necrotizing myopathy
  • Myositis
  • Novel treatments

ASJC Scopus subject areas

  • Rheumatology


Dive into the research topics of 'Promising and Upcoming Treatments in Myositis'. Together they form a unique fingerprint.

Cite this